One Case of Hepatic Dysfunction Induced by Olaparib Tablets

doi:10.19803/j.1672-8629.2019.12.12

Abstract

CLC Number:

R994.11

XU Yinying, JIANG Sunmin. One Case of Hepatic Dysfunction Induced by Olaparib Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 762-764.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2019.12.12

https://zgywjj.magtechjournal.com/EN/Y2019/V16/I12/762

[1] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J].中华肝脏病杂志, 2015, 23(10):1752-1769.
[2] 刘建平, 邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 7(1):12-15.
[3] Moore Kathleen, Colombo Nicoletta, Scambia Giovanni,et al.Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. N Engl J Med, 2018, 379(26):2495-2505.
[4] Friedlander Michael, Matulonis Ursula, Gourley Charlie,et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy[J]. Br J Cancer,2018, 119(9):1075-1085.
[5] Moore K N, Monk B J.Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer[J]. Oncologist, 2016, 21(8):954-63.
[6] Pujadelauraine E, Ledermann J A, Selle F, et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive,relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9):1274-1284.
[7] Robson Mark, Im Seock-Ah, Senkus Elżbieta, et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J Med, 2017,377(6): 523-533.
[8] Bang Yung-Jue, Xu Rui-Hua, Chin Keisho, et al.Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12):1637-1651.
[9] Ledermann Jonathan A, Harter Philipp, Gourley Charlie,et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib main tenance monotherapy: an updated analysis from a randomised,placebo-controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2016, 17(11): 1579-1589.
[10] Oza Amit M, Cibula David, Benzaquen Ana Oaknin, et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial[J]. Lancet Oncol, 2015, 16(1):87-97.
[11] Kaufman B, Shapirafrommer R, Schmutzler R K, et al.Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation[J]. J Clin Oncol,2015, 33(3):244-50.
[12] Domchek S M, Aghajanian C, Shapira-Frommer R, et al.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol,2016, 140(2):199-203.
[13] Liu J F, Barry W T, Birrer M, et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study[J]. Lancet Oncol, 2014, 15(11):1207-1214.
[14] Del Conte G, Sessa C, Von Moos R, et al.Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours[J]. Br J Cancer, 2014, 111(4):651-659.
[15] Balmana J, Tung N M, Isakoff S J, et al.Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors[J]. Ann Oncol, 2014, 25(8):1656-1663.
[16] Choy Edwin, Butrynski James E, Harmon David C, et al.Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy[J].BMC Cancer, 2014, 14(1):1-6.
[17] Ledermann Jonathan, Harter Philipp, Gourley Charlie, et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J]. Lancet Oncol, 2014, 15(8):852-861.
[18] Sandhu S K, Omlin A, Hylands L, et al.Poly (ADP-ribose)polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer[J]. Ann Oncol,2013, 24(5):1416-1418.
[19] Samol J, Ranson M, Scott E, et al.Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study[J].Invest New Drugs, 2012, 30(4):1493-1500.
[20] Ledermann J, Harter P, Gourley C, et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].N Engl J Med, 2012, 366(15):1382-1392.
[21] Kaye S B, Lubinski J, Matulonis U, et al.Phase II, open-label,randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor,and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J]. J Clin Oncol, 2012, 30(4):372-379.
[22] Khan O A, Gore M, Lorigan P, et al.A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436)and dacarbazine in patients with advanced solid tumours[J].Br J Cancer, 2011, 104(5):750-755.
[23] Liu J, Fleming G F, Tolaney S M, et al.A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer[J]. J Clin Oncol, 2011, 29(15):5028-5028.

One Case of Hepatic Dysfunction Induced by Olaparib Tablets

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.